Key result
Amiodarone reduced arrhythmic but not overall mortality post-myocardial infarction, while implantable cardioverter-defibrillators demonstrated superiority over amiodarone in improving overall survival.
Why the study?
Does amiodarone improve survival or reduce arrhythmic recurrence compared to other therapies or ICDs in patients with various cardiac conditions?
Does amiodarone improve survival or reduce arrhythmic recurrence compared to other therapies or ICDs in patients with various cardiac conditions?
This review highlights that while amiodarone reduces arrhythmic mortality in certain populations, ICD therapy is superior for overall survival in high-risk patients with ventricular tachyarrhythmias.
Answers are grounded in this paper and cite their sources.
Supports ICD preference over amiodarone for survival in high-risk patients; leaves open optimal antiarrhythmic strategies in modern practice.
Amiodarone is an antiarrhythmic agent commonly used in the treatment of supraventricular and ventricular tachyarrhythmias. This paper reviews clinical trials in which amiodarone was used in one of the treatment arms. Key post-myocardial infarction trials include EMIAT and CAMIAT, both of which demonstrated that amiodarone reduced arrhythmic but not overall mortality. In patients with congestive heart failure (CHF), amiodarone was associated with a neutral survival in CHF/STAT and improvement in survival in GESICA. In patients with nonsustained ventricular tachycardia, the MADIT trial demonstrated that therapy with an implantable cardioverter-defibrillator (ICD) improved survival compared with the antiarrhythmic drug arm in such patients, most of whom were taking amiodarone. In sustained VT/VF patients, the CASCADE trial demonstrated that empiric amiodarone lowered arrhythmic recurrence rates compared with other drugs guided by serial Holter or electrophysiologic studies. Several trials including AVID, CIDS, and CASH have demonstrated the superiority of ICD therapy compared with empiric amiodarone in improving overall survival. Clinical implications of these trials are discussed.
No takes yet. Share an insight, caveat, or question.
Naccarelli et al. (2000) conducted a review in Supraventricular and ventricular tachyarrhythmias. Amiodarone vs. ICD therapy or other antiarrhythmic drugs was evaluated. Amiodarone reduced arrhythmic but not overall mortality post-myocardial infarction, while implantable cardioverter-defibrillators demonstrated superiority over amiodarone in improving overall survival.
Synapse has enriched 10 related papers. Consider them for comparative context: